ISSN: ISSN: 2157-7412
+44 203 695 8168
President, Genetic and Biomolecular Engineering PBMEF
San Francisco, USA
Marek Malecki MD PhD developed a novel cancer suicide gene therapy. He initially developed it for ovarian cancers as the means of protecting women’s fertility and eliminating risks of genetic diseases in the offspring. It is based upon the novel biotechnology, which he invented and patented. He is currently a Visiting Professor at the UW, Madison and PBMEF, San Francisco. He earned MD degree at the Medical Academy, Poznan followed by Residency/Fellowship in Molecular Medicine in Rigshospitalet, Copenhagen. He earned PhD at the Polish Academy of Sciences, Warsaw followed by the EMBO and AAS postdoctoral fellowships in molecular biology at the Austrian Academy of Sciences, Salzburg, ETH, Zurich, Utrecht University, Utrecht, Cancer Center, Vienna, Cancer Center, Amsterdam, Biozentrum, Basel.
Cancers of ovaries, cancers of testes, cancer stem cells (CSC), circulating tumor cells (CTCs), genetic disorders, iatrogenic genetic mutations, gene therapy, targeted gene delivery, site specific recombination, biotechnology, synthetically antibodies, synthetically modified nucleic acids, fertility sparing therapy, biobanking, in vitro fertilization.